RT Journal Article
T1 Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
A1 Sanchez-Muñoz, Alfonso
A1 Vicioso, Luis
A1 Santonja, Angela
A1 Alvarez, Martina
A1 Plata-Fernandez, Yessica
A1 Miramon, Jose
A1 Zarcos, Irene
A1 Ramirez-Tortosa, Cesar L
A1 Montes-Torres, Julio
A1 Jerez, Jose M
A1 de Luque, Vanessa
A1 Llacer, Casilda
A1 Fernandez-De Sousa, Cristina E
A1 Perez-Villa, Lidia
A1 Alba, Emilio
K1 Biomarkers, tumor
K1 Carcinoma, ductal, breast
K1 Immunohistochemistry
K1 Prognosis
K1 Receptors, estrogen
K1 Área de Gestión Sanitaria Serrania de Malaga
AB Male breast cancer is a rare disease that is still poorly understood. It is mainly classified by immunohistochemistry as a luminal disease. In this study, we assess for the first time the correlation between molecular subtypes based on a validated six-marker immunohistochemical panel and PAM50 signature in male breast cancer, and the subsequent clinical outcome of these different subtypes. We collected 67 surgical specimens of invasive male breast cancer from four different Spanish pathology laboratories. Immunohistochemical staining for the six-marker panel was performed on tissue microarrays. PAM50 subtypes were determined in a research-use-only nCounter Analysis System. We explored the association of immunohistochemical and PAM50 subtypes. Overall survival and disease-free survival were analyzed in the different subtypes of each classification. The distribution of tumor molecular subtypes according PAM50 was: 60% luminal B, 30% luminal A and 10% human epidermal growth factor receptor 2 (Her2) enriched. Only one Her2-enriched tumor was also positive by immunohistochemistry and was treated with trastuzumab. None of the tumors were basal-like. Using immunohistochemical surrogates, 51% of the tumors were luminal B, 44% luminal A, 4% triple-negative and 1% Her2-positive. The clinicopathological characteristics did not differ significantly between immunohistochemical and PAM50 subtypes. We found a significant worse overall survival in Her2-enriched compared with luminal tumors. Male breast cancer seems to be mainly a genomic luminal disease with a predominance of the luminal B subtype. In addition, we found a proportion of patients with Her2-negative by immunohistochemistry but Her2-enriched profile by PAM50 tumors with a worse outcome compared with luminal subtypes that may benefit from anti-Her2 therapies.
PB Elsevier
YR 2017
FD 2017-08-05
LK http://hdl.handle.net/10668/11653
UL http://hdl.handle.net/10668/11653
LA en
NO Sánchez-Muñoz A, Vicioso L, Santonja A, Álvarez M, Plata-Fernández Y, Miramón J, et al. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. Mod Pathol. 2018 Feb;31(2):299-306
NO Wegratefully acknowledge Nanostring Technologies team for providing the reagents for PAM50 subtypes determination as well as technical support, Maria José Lozano for her support with samples immunostaining and Jose M Roldan for the edition of the artwork. Angela Santonja has a predoctoral grant PFIS-ISCIII (FI12/00489).
DS RISalud
RD Apr 10, 2025